Aspirin is First-Line Treatment for Migraine and Episodic Tension-Type Headache Regardless of Headache Intensity

被引:10
作者
Lampl, Christian [1 ]
Voelker, Michael [2 ]
Steiner, Timothy J. [3 ]
机构
[1] Konventhospital Barmherzige Brueder, Dept Neurol, Pain & Headache Ctr, A-4020 Linz, Austria
[2] Bayer HealthCare, Leverkusen, Germany
[3] Norwegian Univ Sci & Technol, Dept Neurosci, N-7034 Trondheim, Norway
来源
HEADACHE | 2012年 / 52卷 / 01期
关键词
aspirin; migraine; tension-type headache; stratified care; stepped care; EFFERVESCENT ACETYLSALICYLIC-ACID; EARLY INTERVENTION; SUMATRIPTAN TABLETS; DOUBLE-BLIND; DISABILITY ASSESSMENT; COST-EFFECTIVENESS; CARE STRATEGIES; PAIN; EFFICACY; ALMOTRIPTAN;
D O I
10.1111/j.1526-4610.2011.01974.x
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objectives. (1) To establish whether pre-treatment headache intensity in migraine or episodic tension-type headache (ETTH) predicts success or failure of treatment with aspirin; and (2) to reflect, accordingly, on the place of aspirin in the management of these disorders. Background.-Stepped care in migraine management uses symptomatic treatments as first-line, reserving triptans for those in whom this proves ineffective. Stratified care chooses between symptomatic therapy and triptans as first-line on an individual basis according to perceived illness severity. We questioned the 2 assumptions underpinning stratified care in migraine that greater illness severity: (1) reflects greater need; and (2) is a risk factor for failure of symptomatic treatment but not of triptans. Methods.-With regard to the first assumption, we developed a rhetorical argument that need for treatment is underpinned by expectation of benefit, not by illness severity. To address the second, we reviewed individual patient data from 6 clinical trials of aspirin 1000 mg in migraine (N = 2079; 1165 moderate headache, 914 severe) and one of aspirin 500 and 1000 mg in ETTH (N = 325; 180 moderate, 145 severe), relating outcome to pre-treatment headache intensity. Results.-In migraine, for headache relief at 2 hours, a small (4.7%) and non-significant risk difference (RD) in therapeutic gain favored moderate pain; for pain freedom at 2 hours, therapeutic gains were almost identical (RD: -0.2%). In ETTH, for headache relief at 2 hours, RDs for both aspirin 500 mg (-4.2%) and aspirin 1000 mg (-9.7%) favored severe pain, although neither significantly; for pain freedom at 2 hours, RDs (-14.2 and -3.6) again favored severe pain. Conclusion.-In neither migraine nor ETTH does pre-treatment headache intensity predict success or failure of aspirin. This is not an arguable basis for stratified care in migraine. In both disorders, aspirin is first-line treatment regardless of headache intensity.
引用
收藏
页码:48 / 56
页数:9
相关论文
共 52 条
  • [1] [Anonymous], 2008, S98074 IMP
  • [2] [Anonymous], 2010, GUID ALL HEALTHC PRO
  • [3] [Anonymous], 2008, S98073 IMP
  • [4] Eletriptan in the early treatment of acute migraine: influence of pain intensity and time of dosing
    Brandes, JL
    Kudrow, D
    Cady, R
    Tiseo, PJ
    Sun, W
    Sikes, CR
    [J]. CEPHALALGIA, 2005, 25 (09) : 735 - 742
  • [5] Defeating migraine pain with triptans: A race against the development of cutaneous allodynia
    Burstein, R
    Collins, B
    Jakubowski, M
    [J]. ANNALS OF NEUROLOGY, 2004, 55 (01) : 19 - 26
  • [6] Analgesic triptan action in an animal model of intracranial pain: A race against the development of central sensitization
    Burstein, R
    Jakubowski, M
    [J]. ANNALS OF NEUROLOGY, 2004, 55 (01) : 27 - 36
  • [7] Randomized, placebo-controlled comparison of early use of frovatriptan in a migraine attack versus dosing after the headache has become moderate or severe
    Cady, R
    Elkind, A
    Goldstein, J
    Keywood, C
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2004, 20 (09) : 1465 - 1472
  • [8] Economic implications of early treatment of migraine with sumatriptan tablets
    Cady, RK
    Sheftell, F
    Lipton, RB
    Kwong, WJ
    O'Quinn, S
    [J]. CLINICAL THERAPEUTICS, 2001, 23 (02) : 284 - 291
  • [9] Treatment of mild headache in disabled migraine sufferers: Results of the spectrum study
    Cady, RK
    Lipton, RB
    Hall, C
    Stewart, WF
    O'Quinn, S
    Gutterman, D
    [J]. HEADACHE, 2000, 40 (10): : 792 - 797
  • [10] Effect of early intervention with sumatriptan on migraine pain: Retrospective analyses of data from three clinical trials
    Cady, RK
    Sheftell, F
    Lipton, RB
    O'Quinn, S
    Jones, M
    Putnam, DG
    Crisp, A
    Metz, A
    McNeal, S
    [J]. CLINICAL THERAPEUTICS, 2000, 22 (09) : 1035 - 1048